Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists

a technology of benzofura and benzothiophene, which is applied in the field of substitution of benzofurans and benzothiophenes, can solve the problems of increased mortality, incapacitation, and increased bone fractures

Inactive Publication Date: 2005-10-13
3 DIMENSIONAL PHARMA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These compounds selectively inhibit αvβ3 and αvβ5 integrins, providing therapeutic benefits in treating cancer, osteoporosis, inflammatory diseases, and other integrin-mediated conditions with improved bioavailability and reduced side effects compared to existing antagonists.

Problems solved by technology

When bone resorbing activity exceeds bone forming activity, the result is osteoporosis, a condition which leads to an increased number of bone fractures, incapacitation and increased mortality.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
  • Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
  • Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of 3-(6-{2-[6-(methylamino)-2-pyridyl]ethoxy}benzo[b]thiophen-3-yl)propanoic acid

a) Synthesis of 3-Iodophenyl acetate

[0169] A solution of 3-iodophenol (3 g, 13.6 mmol), acetyl chloride (2.9 ml, 40.9 mmol) and potassium carbonate (9.42 g,68.2 mmol) in N,N-dimethylforrnamide (75 ml) was stirred for 16 h at room temperature. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with 1N NaOH, dried over magnesium sulfate, and evaporated under vacuum. The crude product was chromatographed over silica gel, eluting with 20% ethyl acetate / hexanes to yield 2.3 g (65%) of 3-iodophenyl acetate.

[0170] NMR 1H Cl3CD δ: 7.57 (1H, m), 7.46 (1H, m), 7.08 92H, m) 2.29 (3H, s).

b) Synthesis of 3-[1,1-bis(Methylethyl)-2-methyl-1-silapropylthio]phenyl acetate

[0171] Triisopropylsilanethiol (2.91 ml, 13.5 mmol) was added dropwise to a suspension of sodium hydride (325 mg, 13.5 mmol) in THF (10 ml). After the evolution of hydrogen ceased, a solution of 3-io...

example 2

Synthesis of 3-{6-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-benzo[b]thiophen-3-yl}-propionic acid

a) 7-(2-Hydroxy-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester

[0188] 7-Ethoxycarbonylmethyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester (synthetic methodology described in WO 00 / 33838) (6.11 g, 19.0 mmol) was dissolved in tetrahydrofuran (40 ml) at room temperature. The solution was place under argon. Lithium borohydride [2M in tetrahydrofuran] (22.8 mmol, 11.43 mL) was carefully added and the reaction was refluxed overnight (16 h). The mixture was poured into a solution of saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered, and evaporated under vacuum to give a crude mixture, which was purified via column chromatography to give 7-(2-hydroxy-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester (49% yield). 1H NMR (Cl3CD), δ: 7.30 (d, 1H,...

example 3

Synthesis of 3-(6-{2-[6-(Methylamino)-2-pyridyl]ethoxy}benzo[b]furan-3-yl)propanoic acid

a) Synthesis of 3-[1,1-bis(Methylethyl)-2-methyl-1-silapropoxy]phenyl acetate

[0192] Lithium bis(trimethylsilyl)amide (73 ml, 73 ml, 1M solution in THF) was added dropwise to a solution of resorcinol monoacetate (10 g, 65.7 mmol) in THF (100 ml) at 78° C. under argon. The solution was stirred for 10 minutes and then triisopropylsilyl chloride (15.5 ml, 73 mmol) was added via syringe. After stirring at room temperature overnight, the mixture was partitioned between water and ethyl acetate. The organic layer was dried, filtered and evaporated under vacuum to yield 13 g of crude 3-[1,1-bis(Methylethyl)-2-methyl-1-silapropoxy]phenyl acetate which was used in the next step without further purification. NMR 1H Cl3CD δ: 7.19 (t, 1H, J=8 Hz), 6.75 (m, 1H), 6.68 (m, 1H), 6.63 (t, 1H, J=4 Hz), 2.29 (s, 3H), 1.25 (m, 3H), 1.11 (d, 18H, J=7.0 Hz).

b) Synthesis of 3-[1,1 -bis(Methylethyl)-2-methyl-1-silaprop...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula I: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, n, i, j and k are defined herein.

Description

[0001] This application claims priority to Provisional application 60 / 324,516, filed Oct. 26, 2001, and also claims priority to Provisional application 60 / 286,532, filed on Apr. 27, 2001.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to novel substituted benzofurans and benzothiophenes that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. [0004] 2. Background Art [0005] Integrins are cell surface glycoprotein receptors which bind extracellular matrix proteins and mediate cell-cell and cell-extracellular matrix interactions (generally referred to as cell adhesion events) (Hynes, R. O., Cell 69:11-25 (1992)). These receptors are composed of noncovalently associated alpha (α) and beta (β) chains which combine to give a variety of heterodimeric proteins with distinct cellular and adhesive specificities (Albeda, S. M., Lab. In...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/4375A61K31/443A61K31/4436A61P3/08A61P7/06A61P9/10A61P19/02A61P19/10A61P25/00A61P25/04A61P25/18A61P25/22A61P25/28A61P25/36A61P29/00A61P35/00C07D405/12C07D409/12C07D471/04
CPCC07D409/12C07D405/12A61P19/02A61P19/10A61P25/00A61P25/04A61P25/18A61P25/22A61P25/28A61P25/36A61P29/00A61P35/00A61P3/08A61P7/06A61P9/10
InventorANACLERIO, BETH M.MARUGAN SANCHEZ, JUAN J.TOMCZUK, BRUCE E.MARDER, VICTOR J.U'PRICHARD, DAVID C.
Owner3 DIMENSIONAL PHARMA